<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CD19-targeted immunotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cd19-targeted-immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 23 Jan 2026 12:29:20 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>CD19-targeted immunotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>CAR T Cell Therapy’s Critical Role in Young Cancer Patients</title>
		<link>https://bioengineer.org/car-t-cell-therapys-critical-role-in-young-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 12:28:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[CD19-targeted immunotherapy]]></category>
		<category><![CDATA[çocuklarda CAR T hücre tedavisi]]></category>
		<category><![CDATA[immunotherapy challenges]]></category>
		<category><![CDATA[İşte içerik için 5 uygun etiket (virgülle ayrılmış): **pediatrik kanser immünoterapisi]]></category>
		<category><![CDATA[Pediatric Oncology]]></category>
		<category><![CDATA[pediatrik CAR T erişimi** **Açıklama:** 1. **pediatrik kanser]]></category>
		<category><![CDATA[solid tümörlerde CAR T zorlukları]]></category>
		<category><![CDATA[tisagenlecleucel]]></category>
		<category><![CDATA[young cancer patients]]></category>
		<guid isPermaLink="false">https://bioengineer.org/car-t-cell-therapys-critical-role-in-young-cancer-patients/</guid>

					<description><![CDATA[Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary approach in the treatment of hematologic malignancies, particularly in pediatric patients with B cell acute lymphoblastic leukemia (B-ALL). The journey from early clinical successes to the landmark FDA approval of tisagenlecleucel, the first gene therapy approved for this indication, has been marked by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319779</post-id>	</item>
	</channel>
</rss>
